Evaluation of EGFR, KRAS and BRAF gene mutations in renal cell carcinoma

A subset of renal cell carcinoma (RCC) patients has been shown to respond to anti-EGFR therapy. As KRAS and BRAF mutations are associated with poor response to anti-EGFR therapy in some cancers, it has been suggested that screening for KRAS and BRAF mutations in RCC may be a promising strategy to id...

Descripción completa

Detalles Bibliográficos
Autores principales: Bayrak, Omer, Sen, Haluk, Bulut, Ersan, Cengiz, Beyhan, Karakok, Metin, Erturhan, Sakip, Seckiner, Ilker
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Codon Publications 2014
Materias:
Short Communication
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5345528/
https://www.ncbi.nlm.nih.gov/pubmed/28326248
http://dx.doi.org/10.15586/jkcvhl.2014.10

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5345528/
https://www.ncbi.nlm.nih.gov/pubmed/28326248
http://dx.doi.org/10.15586/jkcvhl.2014.10

Ejemplares similares